Carolina Carmichael, PA
Physician Assistant · Schertz, TXNPI 1780984393
Payments from drug & device makers
Across 264 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$991
- Novo Nordisk$602
- Lilly USA, LLC$341
- AstraZeneca$328
- Amgen$276
- Astellas Pharma US Inc$211
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,45798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $991 |
| Novo Nordisk | 27 | $602 |
| Lilly USA, LLC | 21 | $341 |
| AstraZeneca | 16 | $328 |
| Amgen | 17 | $276 |
| Astellas Pharma US Inc | 7 | $211 |
| GSK | 10 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $163 |
| Sunovion Pharmaceuticals Inc. | 10 | $137 |
| Pfizer | 8 | $133 |
| Amarin Pharma, Inc. | 6 | $129 |
| Bayer | 5 | $114 |
| Abbott | 5 | $106 |
| Novartis | 6 | $102 |
| Merck | 7 | $101 |
| Kowa Pharmaceuticals America, Inc. | 5 | $83 |
| Biohaven Pharmaceuticals, Inc. | 4 | $78 |
| Boehringer Ingelheim | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $37 |
| Acerus Pharmaceuticals Corporation | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Antares Pharma, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$124
How this compares
$4,557 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $85,766 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $48,442 |
| MounjaroTirzepatide | 25 | $38,723 |
| JardianceEmpagliflozin | 24 | $31,447 |
| FarxigaDapagliflozin Propanediol | 15 | $21,279 |
| LinzessLinaclotide | 12 | $16,208 |
| JanuviaSitagliptin Phosphate | 16 | $14,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,134 |
| MyrbetriqMirabegron | 18 | $9,342 |
| Dexlansoprazole DrDexlansoprazole | 18 | $7,292 |
| VascepaIcosapent Ethyl | 13 | $5,617 |
| Gabapentin | 67 | $1,598 |
| Atorvastatin Calcium | 160 | $1,527 |
| Rosuvastatin Calcium | 114 | $1,462 |
| Levothyroxine Sodium | 122 | $1,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $602 | $85,76646 claims |
| Lilly USA, LLCMounjaro | $341 | $38,72325 claims |
| Boehringer IngelheimJardiance | $64 | $31,44724 claims |
| AstraZenecaFarxiga | $328 | $21,27915 claims |
| AbbVieLinzess, Synthroid | $991 | $16,85628 claims |
| MerckJanuvia | $101 | $14,70216 claims |
| GSKTrelegy Ellipta | $177 | $12,13411 claims |
| Astellas Pharma US IncMyrbetriq | $211 | $9,34218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Schertz
- Victoria Soto MartinezSchertz$35K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.